Last reviewed · How we verify
Placebo to Raltegravir
Placebo to Raltegravir is a Integrase strand transfer inhibitor (INSTI) Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in pediatric patients.
Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.
Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in pediatric patients.
At a glance
| Generic name | Placebo to Raltegravir |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Raltegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the human genome, thereby halting HIV replication and reducing viral load. This mechanism is distinct from reverse transcriptase or protease inhibitors and represents the integrase inhibitor class of antiretrovirals.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in pediatric patients
Common side effects
- Diarrhea
- Nausea
- Headache
- Insomnia
- Elevated creatine kinase
Key clinical trials
- Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY (PHASE3)
- Combination Antiretroviral Therapy (cART) for PBC (PHASE2)
- Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load (PHASE2)
- Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers (PHASE1)
- Raltegravir Intensification in HIV-infected Patients (PHASE4)
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (PHASE3)
- Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults (PHASE1)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Raltegravir CI brief — competitive landscape report
- Placebo to Raltegravir updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to Raltegravir
What is Placebo to Raltegravir?
How does Placebo to Raltegravir work?
What is Placebo to Raltegravir used for?
Who makes Placebo to Raltegravir?
What drug class is Placebo to Raltegravir in?
What development phase is Placebo to Raltegravir in?
What are the side effects of Placebo to Raltegravir?
What does Placebo to Raltegravir target?
Related
- Drug class: All Integrase strand transfer inhibitor (INSTI) drugs
- Target: All drugs targeting HIV integrase
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in pediatric patients
- Compare: Placebo to Raltegravir vs similar drugs
- Pricing: Placebo to Raltegravir cost, discount & access